- Home
- IMVT
IMVT
Immunovant Inc.
as 10-17-2024 4:00pm EST
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $48.91 | AVG Volume (30 days): | 847.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $24.67 - $45.58 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Immunovant Inc. (IMVT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Barnett Eva Renee | IMVT | Chief Financial Officer | Oct 9 '24 | Sell | $29.56 | 5,162 | $152,588.72 | 338,614 | |
| Salzmann Peter | IMVT | Chief Executive Officer | Oct 9 '24 | Sell | $29.56 | 4,460 | $131,837.60 | 1,003,884 | |
| Macias William L. | IMVT | Chief Medical Officer | Aug 21 '24 | Sell | $32.08 | 3,027 | $96,437.28 | 368,332 | |
| Barnett Eva Renee | IMVT | Chief Financial Officer | Aug 21 '24 | Sell | $32.08 | 3,768 | $120,044.64 | 338,614 | |
| Levine Mark S. | IMVT | Chief Legal Officer | Aug 21 '24 | Sell | $32.08 | 3,295 | $104,975.68 | 330,099 | |
| Salzmann Peter | IMVT | Chief Executive Officer | Aug 21 '24 | Sell | $32.08 | 15,068 | $480,052.16 | 1,003,884 | |
| Butchko Julia G. | IMVT | Chief Development Officer | Aug 21 '24 | Sell | $32.08 | 3,027 | $96,437.28 | 441,079 | |
| Levine Mark S. | IMVT | Chief Legal Officer | Jul 24 '24 | Sell | $27.76 | 4,015 | $111,456.40 | 330,099 | |
| Geffner Michael | IMVT | Chief Medical Officer | Jul 24 '24 | Sell | $27.76 | 3,456 | $95,938.56 | 138,160 | |
| Stout Jay S | IMVT | Chief Technology Officer | Jul 24 '24 | Sell | $27.76 | 2,813 | $78,088.88 | 144,926 |
Latest Immunovant Inc. News
IMVT Breaking Stock News: Dive into IMVT Ticker-Specific Updates for Smart Investing
MT Newswires
9 days ago
Oppenheimer Adjusts Immunovant Price Target to $53 From $47, Maintains Outperform Rating
Insider Monkey
17 days ago
Is Immunovant, Inc. (IMVT) the Worst Performing Stock to Buy on the Dip?
Insider Monkey
17 days ago
Is Roivant Sciences Ltd. (NASDAQ:ROIV) The Best NASDAQ Stock Under $50 To Buy?
MT Newswires
a month ago
Citigroup Raises Immunovant's Price Target to $60 From $51, Buy Rating Maintained
Benzinga
a month ago
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
Pharmaceutical Technology
a month ago
Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses
Zacks
a month ago
IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab
MT Newswires
a month ago
Immunovant's Graves' Disease Drug Shows Improved Efficacy at Higher Doses
Compare IMVT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMVT Immunovant Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.